Mario A Eisenberger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6600539/publications.pdf

Version: 2024-02-01

65 papers	9,216 citations	182225 30 h-index	134545 62 g-index
67 all docs	67 docs citations	67 times ranked	10512 citing authors

#	Article	IF	Citations
1	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸F-DCFPyL. Molecular Imaging, 2022, 2022, 7056983.	0.7	6
2	Association between baseline body mass index and survival in men with metastatic hormoneâ€sensitive prostate cancer: ECOGâ€ACRIN CHAARTED E3805. Prostate, 2022, 82, 1176-1185.	1.2	2
3	Neutropenia, neutrophilia, and neutrophilâ€“lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211000.	1.4	4
4	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	2.6	52
5	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	0.9	49
6	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 387-395.	0.4	19
7	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	0.9	61
8	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€“Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	2.8	24
9	Nivolumab plus ipilimumab, with or without enzalutamide, in ARâ€V7â€expressing metastatic castrationâ€resistant prostate cancer: A phaseâ€2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	1.2	35
10	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer, 2021, 144, 302-309.	1.3	29
11	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. Cancers, 2021, 13, 1284.	1.7	6
12	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	0.8	65
13	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.2	2
14	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. Journal of Urology, 2021, 206, 623-629.	0.2	4
15	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. European Journal of Cancer, 2020, 125, 142-152.	1.3	7
16	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 2020, 20, 492.	1.1	16
17	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
18	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology, 2020, 101, 70-79.	1.1	5

#	Article	IF	Citations
19	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.4	37
20	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	1.1	3
21	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Human Pathology, 2019, 87, 95-102.	1.1	34
22	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-14.	1.5	23
23	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology, 2019, 76, 452-458.	0.9	109
24	Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer â€" Playing the Right CARD. New England Journal of Medicine, 2019, 381, 2564-2566.	13.9	5
25	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	1.2	21
26	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	0.9	48
27	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncology, The, 2018, 19, 76-86.	5.1	149
28	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. Journal of Clinical Oncology, 2018, 36, 376-382.	0.8	75
29	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	0.8	129
30	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	0.9	256
31	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	3.2	122
32	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
33	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancerâ€"PROSELICA. Journal of Clinical Oncology, 2017, 35, 3198-3206.	0.8	218
34	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-NaÃ¯ve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	0.8	73
35	Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, 2017, 8, 15651-15662.	0.8	20
36	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 411-419.	1.3	202

#	Article	IF	Citations
37	Bipolar Androgen Therapy for Men With Androgen Ablation NaÃ¯ve Prostate Cancer: Results From the Phase II BATMAN Study. Prostate, 2016, 76, 1218-1226.	1.2	63
38	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptorâ€directed therapies. Prostate, 2016, 76, 512-520.	1.2	19
39	Comparison of Prostate-Specific Membrane Antigenâ€“Based ¹⁸F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-NaÃ¯ve and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 46-53.	2.8	111
40	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. Prostate, 2015, 75, 1518-1525.	1.2	88
41	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2015, 1, 582.	3.4	552
42	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine, 2015, 7, 269ra2.	5.8	205
43	AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 138-138.	0.8	14
44	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.. Journal of Clinical Oncology, 2015, 33, 336-336.	0.8	3
45	Metformin use and outcome of sunitinib treatment in diabetic patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 440-440.	0.8	1
46	Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC).. Journal of Clinical Oncology, 2015, 33, 429-429.	0.8	0
47	A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2015, 33, 360-360.	0.8	2
48	Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. Urology, 2014, 83, 1444.e1-1444.e6.	0.5	19
49	Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature, 2014, 515, 134-137.	13.7	284
50	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine, 2014, 371, 1028-1038.	13.9	2,233
51	Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study. European Urology, 2014, 66, 330-336.	0.9	48
52	Maximal Testosterone Suppression in Prostate Cancerâ€”Free vs Total Testosterone. Urology, 2014, 83, 1217-1222.	0.5	16
53	The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.. Journal of Clinical Oncology, 2013, 31, 44-44.	0.8	2
54	Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx).. Journal of Clinical Oncology, 2013, 31, 160-160.	0.8	0

#	Article	IF	Citations
55	Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D).. Journal of Clinical Oncology, 2013, 31, 146-146.	0.8	0
56	Are there geographic differences inÂthe outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?. Journal of Clinical Oncology, 2013, 31, 458-458.	0.8	0
57	Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su).. Journal of Clinical Oncology, 2012, 30, e15058-e15058.	0.8	1
58	Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) inÂmetastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model.. Journal of Clinical Oncology, 2012, 30, 37-37.	0.8	1
59	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	0.8	1,960
60	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology, 2004, 63, 114-119.	0.5	19
61	Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. Journal of Clinical Oncology, 2000, 18, 1440-1450.	0.8	176
62	COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?. Journal of Urology, 2000, 164, 3-9.	0.2	100
63	The experience with suramin in advanced prostate cancer. Cancer, 1995, 75, 1927-1934.	2.0	10
64	Southwest oncology group strategies in prostatic carcinoma. Journal of Surgical Oncology, 1995, 11, 60-64.	1.4	9
65	Identification of endothelinâ€“1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine, 1995, 1, 944-949.	15.2	590